KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Goodwill (2016 - 2025)

Vertex Pharmaceuticals has reported Goodwill over the past 17 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Goodwill at $1.1 billion for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (changed 0.0% YoY), and the annual figure for FY2025 was $1.1 billion, changed 0.0%.
  • Goodwill for Q4 2025 was $1.1 billion at Vertex Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Over the last five years, Goodwill for VRTX hit a ceiling of $1.1 billion in Q4 2024 and a floor of $1.0 billion in Q1 2021.
  • Median Goodwill over the past 5 years was $1.1 billion (2022), compared with a mean of $1.1 billion.
  • Biggest five-year swings in Goodwill: changed 0.0% in 2021 and later increased 8.56% in 2022.
  • Vertex Pharmaceuticals' Goodwill stood at $1.0 billion in 2021, then rose by 8.56% to $1.1 billion in 2022, then changed by 0.0% to $1.1 billion in 2023, then increased by 1.1% to $1.1 billion in 2024, then changed by 0.0% to $1.1 billion in 2025.
  • The last three reported values for Goodwill were $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025) per Business Quant data.